AstraZeneca is pressing into the oral obesity market with elecoglipron, positioning for later-stage studies after two Phase 2 readouts presented at the ADA meeting. The company is aiming to secure a foothold as competitors—including Eli Lilly and Novo Nordisk—expand injectable and oral incretin franchises. A separate set of ADA coverage highlighted that the broader obesity pipeline is increasingly judged by both weight-loss magnitude and tolerability signals as companies attempt to differentiate in a crowded class. For AZ, early efficacy and regimen-related endpoints are being treated as the key decision inputs for the next pivotal step. Together, the developments signal that oral GLP-1s are moving from concept to competitive product strategy, with timelines and dose-framing becoming the central battleground for market share.